Target intelligence / Profile preview

Triosephosphate isomerase 1 (TPI1)

Target
TPI1
Molecular classification
Enzyme, Isomerase, TIM barrel protein
01

Overview

Triosephosphate isomerase 1 (TPI1) is a highly conserved, homodimeric enzyme essential for glycolysis, catalyzing the reversible interconversion of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate without cofactors. It is structurally characterized by the TIM barrel fold and displays “catalytic perfection,” limited only by substrate diffusion rates. TPI1 is expressed in almost all eukaryotes and many prokaryotes, with additional non-canonical functions being investigated, such as nuclear signaling relationships and contributions to cancer biology. Deficiency or malfunction due to genetic mutations causes severe, early-onset anemia, neuromuscular and metabolic dysfunction, reflecting its indispensability for cellular energy production. While not a current direct drug target, the enzyme’s central role in metabolism and implications for disease make it an area of active research.

Other names
Triosephosphate isomeraseTPITIMTriose-phosphate isomeraseMethylglyoxal synthaseHEL-S-49TPIDepididymis secretory protein Li 49
02

Mechanism of action

Chemical inhibitors bind at the active site, competing with substrate or mimicking transition states, thus blocking isomerase activity

03

Biological functions

Glycolysis (interconversion of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate)GluconeogenesisFatty acid biosynthesisPentose phosphate pathwayCellular energy production"Moonlighting" non-catalytic roles, including involvement in nuclear signaling and cancer pathogenesis
04

Disease associations

Triosephosphate isomerase deficiency (rare glycolytic enzymopathy; pediatric anemia, neuromuscular impairment, susceptibility to infection)Cancer (nuclear roles implicated in pathogenesis and chemotherapy resistance)Other metabolic diseases (due to role in glycolysis and energy homeostasis)
05

Safety considerations

Loss-of-function mutations lead to severe multisystem disease. Targeting TPI1 may risk toxicity due to central role in metabolism and energy productionFormation of toxic metabolites (e.g., methylglyoxal) if glycolytic function is impaired
06

Interacting drugs

No approved drugs directly target TPI1 clinically. Research chemicals/inhibitors (e.g., 2-phosphoglycolate, arsenate, D-glycerol-1-phosphate) have been used in experimental studies
07

Biomarkers

Reduced TPI1 activity or protein levels (diagnostic marker for TPI deficiency)Expression/aberrant localization (investigated in cancer and metabolic disorders)

Beyond the preview

Go deeper on Triosephosphate isomerase 1 (TPI1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triosephosphate isomerase 1 (TPI1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call